Prognostic impact of MYC/BCL2 coexpression in DLBCL is independent of MYC/BCL2 corearrangement and TP53 mutation status. (A-B) OS (A) and PFS (B) of patients with MYC/BCL2 double-hit DLBCL. (C-D) OS (C) and PFS (D) of patients with MYC⁺BCL2⁺ DLBCL in the absence of MYC/BCL2 double hit. (E) OS of patients with MYC⁺BCL2⁺ DLBCL in the absence of TP53 mutation. (F) Prognostic impact of TP53 mutation in MYC⁺BCL2⁺ DLBCL.